share_log

TC BioPharm | 8-K: Current report

SEC announcement ·  Mar 18 20:04
Summary by Futu AI
On March 12, 2024, TC BioPharm (Holdings) PLC, a Scotland-based biopharmaceutical company, reported the issuance of 623,750 American Depositary Shares (ADSs) representing 12,475,000 ordinary shares. This issuance was the result of the exercise of outstanding warrants that were initially issued on August 30, 2023, and disclosed in a Report of Foreign Private Issuer filed with the SEC the following day. The transaction generated gross cash proceeds of approximately £986,398 (around $1,263,000) for TC BioPharm. The ADSs were issued under the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act. The company, which is registered with the United States Securities and Exchange Commission and listed on The Nasdaq Stock Market LLC, is identified as an emerging growth company.
On March 12, 2024, TC BioPharm (Holdings) PLC, a Scotland-based biopharmaceutical company, reported the issuance of 623,750 American Depositary Shares (ADSs) representing 12,475,000 ordinary shares. This issuance was the result of the exercise of outstanding warrants that were initially issued on August 30, 2023, and disclosed in a Report of Foreign Private Issuer filed with the SEC the following day. The transaction generated gross cash proceeds of approximately £986,398 (around $1,263,000) for TC BioPharm. The ADSs were issued under the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act. The company, which is registered with the United States Securities and Exchange Commission and listed on The Nasdaq Stock Market LLC, is identified as an emerging growth company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.